GlassScriptPhysician profile
Mabel Martinez
NPI 1386314052
$6,024.76
in general payments reported to CMS, 2019-2025
32 companies · $2,158 in 2025
The $2,158 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.85 · 2022: $412 · 2023: $1,418 · 2024: $1,958 · 2025: $2,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,532.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,001.05 | 2022-2025 | |
| Axsome Therapeutics, INC. | $920.92 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $612.67 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Novartis Pharmaceuticals Corporation | $385.17 | 2024-2025 | |
| Indivior INC. | $316.52 | 2023-2025 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $311.35 | 2022-2025 | Cobenfy, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $280.19 | 2022-2025 | Trintellix |
| Alkermes, INC. | $265.92 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Almatica Pharma LLC | $245.52 | 2023-2025 | Loreev Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $242.10 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $238.20 | 2023-2025 | Spravato, Invega Sustenna, Xarelto |
| Neurocrine Biosciences, INC. | $222.18 | 2022-2025 | Ingrezza |
| Corium, LLC | $158.91 | 2023-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $135.35 | 2023-2025 | Austedo Xr, Austedo Xr |
| Amgen INC. | $123.72 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $118.95 | 2023-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $63.21 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $58.29 | 2021-2022 | |
| 180 Medical, INC. | $46.99 | 2022-2023 | Cure Catheter |
| Exact Sciences Corporation | $40.62 | 2023 | Cologuard Collection Kit |
| Braeburn INC. | $37.48 | 2025 | Brixadi |
| Sumitomo Pharma America, INC. | $20.96 | 2023 | Gemtesa |
| Pfizer INC. | $19.82 | 2023 | |
| Myriad Genetic Laboratories, INC. | $19.15 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.97 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $18.34 | 2022 | |
| Redhill Biopharma INC. | $18.25 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.24 | 2023 | Onpattro |
| Idorsia Pharmaceuticals US INC | $18.03 | 2023 | Quviviq |
| Amarin Pharma, INC. | $17.20 | 2023 | |
| Glaxosmithkline, LLC. | $16.66 | 2022 | |
| Angiodynamics, INC. | $13.83 | 2023 | Nanoknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mabel Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.